J
Jesús Millán
Researcher at Hospital General Universitario Gregorio Marañón
Publications - 79
Citations - 1788
Jesús Millán is an academic researcher from Hospital General Universitario Gregorio Marañón. The author has contributed to research in topics: Diabetes mellitus & Lipid profile. The author has an hindex of 18, co-authored 74 publications receiving 1565 citations. Previous affiliations of Jesús Millán include Autonomous University of Madrid & University of Barcelona.
Papers
More filters
Journal ArticleDOI
Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention
Jesús Millán,Xavier Pintó,Anna Muñoz,Manuel Zúñiga,Joan Rubiés-Prat,Luis Felipe Pallardo,Luis Masana,Alipio Mangas,Antonio Hernández-Mijares,Pedro González-Santos,Juan F. Ascaso,Juan Pedro-Botet +11 more
TL;DR: Future recommendations regarding the diagnosis and treatment of dyslipidemia should include the lipoprotein ratios with greater predictive power which, in view of the evidence-based results, are none other than those which include HDL cholesterol.
Journal ArticleDOI
Tablas de evaluación del riesgo coronario adaptadas a la población española. Estudio DORICA
Javier Aranceta,Carmen Pérez Rodrigo,Màrius Foz Sala,Teresa Mantilla,Lluís Serra Majem,Basilio Moreno,Susana Monereo,Jesús Millán,Grupo Colaborativo para el estudio Dorica fase +8 more
TL;DR: In this paper, the authors present unas ta-blas de riesgo coronario confeccionadas a partir de the ecuacion de Framingham adaptada a the prevalencia of factores de riego in Espana.
Journal ArticleDOI
Prevalencia y caracteristicas de la dislipemia en pacientes en prevencion primaria y secundaria tratados con estatinas en Espana. Estudio DYSIS-Espana
José Ramón González-Juanatey,Jesús Millán,Eduardo Alegría,Carlos Guijarro,Jose V. Lozano,Gustavo C. Vitale +5 more
TL;DR: Most patients who received statin therapy, particularly those at high cardiovascular risk, were not at the normal lipid parameter levels according to cardiovascular guidelines, and the management of lipid levels in Spain still has potential for improvement.
Journal ArticleDOI
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapy
Carlos Aguiar,Eduardo Alegría,Riccardo C. Bonadonna,Alberico L. Catapano,Francesco Cosentino,Moses Elisaf,Michel Farnier,Jean Ferrières,Pasquale Perrone Filardi,Nicolae Hancu,Meral Kayıkçıoğlu,Alberto Mello e Silva,Jesús Millán,Željko Reiner,Lale Tokgozoglu,Paul Valensi,Margus Viigimaa,Michal Vrablík,Alberto Zambon,José Luis Zamorano,Roberto Ferrari +20 more
TL;DR: Favourable safety and clinical data support the combination of statins with other lipid-lowering agents, such as fenofibrate-statin combination therapy, and in patients with AD, achieving target non-HDL-c levels should be a key focus of CV risk management.
Journal ArticleDOI
Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Juan F. Ascaso,Pedro González Santos,Antonio Hernández Mijares,Alipio Mangas Rojas,Luis Masana,Jesús Millán,Luis Felipe Pallardo,Juan Pedro-Botet,Francisco Pérez Jiménez,Xavier Pintó,Ignacio Plaza,Juan Rubiés,Manuel Zúñiga +12 more
TL;DR: Fibrates and HMG-CoA reductase inhibitors (statins) are the most effective drugs in controlling the metabolic syndrome hyperlipidemia, and are thus the drugs of first choice.